Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Brain Neoplasms 264Glioblastoma 245Glioma 187Neuroblastoma 83Neoplasms 58Central Nervous System Neoplasms 53Astrocytoma 53Medulloblastoma 45Breast Neoplasms 42Sarcoma 38Melanoma 38Carcinoma, Non-Small-Cell Lung 37Neurofibromatosis 1 36Meningioma 35Ependymoma 35Lung Neoplasms 34Osteosarcoma 29Rhabdomyosarcoma 28Diffuse Intrinsic Pontine Glioma 27Sarcoma, Ewing 26Recurrence 26Rhabdoid Tumor 25Neoplasm Metastasis 25Oligodendroglioma 22Wilms Tumor 21Gliosarcoma 21Pancreatic Neoplasms 20Pheochromocytoma 19Hepatoblastoma 19Thyroid Neoplasms 18

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Mesothelial × CNS × 90 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡